Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML

Akriti G Jain,Quinto Gesiotto,Somedeb Ball, Lisa Nodzon, Amanda Rodriguez, Onyee Chan, Eric Padron, Andrew Kuykendall, Rami Komrokji, David A. Sallman, Jeffrey E Lancet, Javier Pinilla-Ibarz, Kendra Sweet

Annals of Hematology（2024）

引用 0|浏览0

暂无评分

摘要

Dasatinib is one of the second generation tyrosine kinase inhibitors (TKI) which is approved for the treatment of patients with chronic phase CML (CP-CML) both in the front line and in the second line setting. Pleural effusion (PE) is a unique toxicity associated with dasatinib use. Our aim was to study the incidence of pleural effusion in our cohort of patients who were treated with dasatinib for CP-CML and the safety upon TKI switch. A total of 390 patients were treated with dasatinib during their course of treatment for CP-CML. A total of 69 patients (17.6

查看译文

关键词

Chronic myeloid leukemia,Tyrosine kinase inhibitors,TKI,CML,Adverse events,Dasatinib

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要